A study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma To estimate the frequency of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation in a new mutation analysis triggered by a mutant plasma cell-free DNA (cfDNA) test result, for pati...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - To demonstrate effectiveness of once-monthly subcutaneous (sc) administration of RO0503821 for anemia management in patients with chronic kidney disease (CKD) who are not on dialysis previously re...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose Abnormalities To determine whether the addition of aleglitazar versus placebo will reduce a composite outcome of CV death, non-fatal myocardial infarction or non-fatal stroke in patients with stable CVD and glucose...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response • To evaluate the effect of PEGASYS® (peginterferon alfa-2a 40KD) plus COPEGUS® (ribavirin) combination therapy given for 24 weeks versus 48 weeks on the clearance of HCV viremia 24 weeks after treatm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy • To assess the safety and tolerability of tocilizumab (TCZ) monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active R...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of RO7009789 in Combination with MPDL3280A in Patients with Locally Advanced and Metastatic Solid Tumors Estudio de RO7009789 en combinación con MPDL3280A en pacientes con tumores sólidos localmente avanzados y/o metastásicos Part IA: - safety, tolerability of sequential single-dose (SD) RO7009789 intravenous (IV) and MPDL3280A (here: MPDL) - safety, tolerability of sequential SD RO7009789 subcutaneous (SC) and MPDL - sing...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the effect of Aleglitazar on responsiveness (sensitivity) to insulin in patients with type 2 diabetes Efficacy: To evaluate the effect of aleglitazar on whole body insulin sensitivity compared with placebo after 16 weeks of treatment in patients with T2D inadequately controlled with metformin monothe...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old • To evaluate the pharmacokinetics of saquinavir that, when boosted with ritonavir, provides a systemic exposure in HIV-1 infected infants and children 4 months to < 6 years similar to that which has ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate both patients' preference and doctors' and nurses' satisfaction with subcutaneous administration(under the skin) of trastuzumab in patients with breast cancer To evaluate the proportion of patients indicating an overall preference for either the subcutaneous (SC) or the intravenous (IV) route of administration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib versus Placebo and Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis 1. To evaluate the efficacy of vismodegib plus ruxolitinib compared with ruxolitinib plus placebo in patients with intermediate- or high-risk myelofibrosis (MF), as measured by spleen response rate at...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune